Simon Thompson

3 days ago | investorschronicle.co.uk | Simon Thompson

• £7.1mn tender offer complete• Net cash position• Deep discount to sum-of-the-parts valuationAim-traded alternative broadband services provider Bigblu Broadband’s (BBB:21p) main focus is on reducing central costs and maximising shareholder value from its retained equity stakes in former Australian subsidiary SkyMesh (£6.8mn), and Quickline (£5.9mn), a company building fixed wireless access networks to address the ‘UK digital divide’.

4 days ago | investorschronicle.co.uk | Simon Thompson

• 2024 pre-tax profit of £20.9mn• Diluted earnings per share of 24.5p• 16.8 per cent total shareholder return• Double-digit NAV growth • 20p-a-share proposed shareholder capital returnAim-traded Helios Underwriting (HUW:247p), the only publicly traded investment company offering access to the underwriting profits from a diverse portfolio of Lloyd’s of London syndicates, increased net asset value (NAV) per share by 11 per cent to 243p in 2024.

4 days ago | investorschronicle.co.uk | Simon Thompson

• Full-year revenue up 30 per cent to $0.8mn• Operating loss widened from $3.3mn to $5.8mn• Post-year-end oversubscribed equity raise• Bulk orders growing stronglyAim-traded MicroSalt (SALT:65.5p) is potentially a major disrupter in the food market. The company is commercialising a patented technology that produces full-flavour low-sodium salt to reduce excess sodium consumption.

6 days ago | bachtrack.com | Simon Thompson

Even in Scotland the summer seems to have arrived, and the warmth outside the Usher Hall seemed to generate the perfect conditions to listen to the Royal Scottish National Orchestra playing Debussy’s languid Prélude à l'après-midi d'un faune, perhaps the most sensuous hymn to summer heat ever composed.

1 week ago | investorschronicle.co.uk | Simon Thompson

• Major client cancels contract• Guidance for full-year operating loss • Net cash position impacted• 2026 recovery forecast by analystshVIVO (HVO:7.75p) has announced a significant contract cancellation alongside a postponement and a smaller study cancellation that has led to material earnings downgrades. The company is a specialist contract research organisation (CRO) that tests infectious and respiratory disease vaccines and antivirals using human challenge clinical trials.